November 28, 2025 a 04:38 pm
ELV: Analysts Ratings - Elevance Health Inc.
Elevance Health Inc. has seen a steady analyst interest, reflecting its considerable role in the health benefits sector. With its comprehensive care solutions for 118 million people, analyst ratings have shown consistent confidence, predominantly favoring Buy recommendations. Despite minor fluctuations, the sentiment remains largely positive, hinting at a robust market position.
Historical Stock Grades
| Recommendation | Count | Score |
|---|---|---|
| Strong Buy | 4 | |
| Buy | 10 | |
| Hold | 7 | |
| Sell | 0 | |
| Strong Sell | 0 |
Sentiment Development
Over the past months, the sentiment for Elevance Health has demonstrated slight shifts, with a consistent base of "Buy" ratings. However, a minor reduction in "Strong Buy" suggests some skepticism, possibly related to broader market conditions or specific company developments:
- The number of overall analyst ratings has remained relatively stable.
- A consistent presence of "Buy" recommendations underscores solid confidence.
- "Hold" ratings have seen a minor increase, indicating caution.
Percentage Trends
Analyzing the percentage shifts reveals subtle changes in analyst confidence. Notably, the "Strong Buy" category saw a contraction, while "Hold" ratings slightly increased:
- November 2025 shows a mix of strong and moderate buys, with a larger proportion in the "Buy" category (60%).
- A slight contraction in "Strong Buy" percentage suggests a moderating bullish sentiment.
- "Hold" ratings' rise hints at a cautious optimism or potential reassessment of risks.
Latest Analyst Recommendations
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-11-26 | Buy | Buy | TD Cowen |
| 2025-11-04 | Outperform | Outperform | Mizuho |
| 2025-10-28 | Overweight | Overweight | JP Morgan |
| 2025-10-23 | Buy | Buy | TD Cowen |
| 2025-10-22 | Overweight | Overweight | Barclays |
Analyst Recommendations with Change of Opinion
Within the past months, several analysts have adjusted their ratings, indicating shifts in perception or broader market conditions. Changes include both upgrades and downgrades, showcasing varied confidence levels:
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-07-21 | Hold | Buy | Argus Research |
| 2025-07-18 | Market Perform | Outperform | Leerink Partners |
| 2025-04-15 | Neutral | Outperform | Baird |
| 2025-03-17 | Buy | Hold | Argus Research |
| 2024-10-18 | Hold | Buy | Argus Research |
Interpretation
Recent analyst activity around Elevance Health points to a resilient yet adaptable sentiment. While consistent "Buy" recommendations underscore confidence in its strategic direction, the increase in "Hold" ratings suggests caution, perhaps due to external market pressures or sector-specific challenges. These mixed signals illustrate a balanced view with moderate risk considerations, highlighting an environment of cautious optimism.
Conclusion
Elevance Health Inc.'s stock demonstrates potential grounded in solid analyst confidence, particularly in its positioning within the health benefits sector. Though stability is largely observed through a dominant "Buy" sentiment, emerging "Hold" recommendations hint at potential volatility or sectoral shifts. Investors may consider this as an opportunity, balancing evident growth potential against a backdrop of cautionary stances. Viewing early indicators, careful market observation remains crucial.